WallStreetZenWallStreetZen

NASDAQ: VRTX
Vertex Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for VRTX

Based on 17 analysts offering 12 month price targets for Vertex Pharmaceuticals Inc

Min Forecast
$350.00-35.22%
Avg Forecast
$562.71+4.15%
Max Forecast
$641.00+18.65%

Should I buy or sell VRTX stock?

Based on 17 analysts offering ratings for Vertex Pharmaceuticals Inc.

Strong Buy
Strong Buy
11 analysts 64.71%
Buy
4 analysts 23.53%
Hold
1 analysts 5.88%
Sell
1 analysts 5.88%
Strong Sell
0 analysts 0%
Although VRTX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates VRTX as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their VRTX stock forecasts and price targets.

VRTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-08-05
lockedlocked$00.00+00.00%2026-08-05Find Out Why
lockedlocked$00.00+00.00%2026-08-04Find Out Why
lockedlocked$00.00+00.00%2026-08-04Find Out Why
lockedlocked$00.00+00.00%2026-08-04
UBS
Top 9%
92
Strong BuyMaintains$585.00+8.28%2026-07-13
RBC Capital
Top 9%
92
BuyMaintains$570.00+5.50%2026-07-07
Baird
Top 15%
86
SellMaintains$350.00-35.22%2026-07-07
Morgan Stanley
Top 5%
96
Strong BuyMaintains$616.00+14.02%2026-05-05Find out why
Bernstein
Top 34%
67
BuyMaintains$572.00+5.87%2026-05-05

1 of 2

Forecast return on equity

Is VRTX forecast to generate an efficient return?

Company
36.48%
Industry
15.45%
Market
168.37%
VRTX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is VRTX forecast to generate an efficient return on assets?

Company
26.94%
Industry
23.26%
VRTX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

VRTX earnings per share forecast

What is VRTX's earnings per share in the next 3 years based on estimates from 33 analysts?

Avg 1 year Forecast
$19.34+11.58%
Avg 2 year Forecast
$21.28+22.8%
Avg 3 year Forecast
$25.16+45.15%
VRTX's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

VRTX revenue forecast

What is VRTX's revenue in the next 3 years based on estimates from 33 analysts?

Avg 1 year Forecast
$13.3B+5.87%
Avg 2 year Forecast
$14.7B+16.48%
Avg 3 year Forecast
$16.4B+30.53%
VRTX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

VRTX earnings growth forecast

How is VRTX forecast to perform vs Biotechnology companies and vs the US market?

Company
12.65%
Industry
10.53%
Market
30.27%
VRTX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
VRTX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
VRTX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

VRTX revenue growth forecast

How is VRTX forecast to perform vs Biotechnology companies and vs the US market?

Company
9.1%
Industry
32.77%
Market
13.34%
VRTX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
VRTX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

VRTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VRTX$540.26$562.71+4.15%Strong Buy
REGN$826.64$800.74-3.13%Strong Buy
NVO$46.14$41.00-11.14%Hold
ARGX$1,038.12$1,143.07+10.11%Strong Buy
MRNA$133.32$71.30-46.52%Hold
View Top Biotech Stocks

Vertex Pharmaceuticals Stock Forecast FAQ

Is Vertex Pharmaceuticals Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 17 Wall Street analysts covering (NASDAQ: VRTX) stock is to Strong Buy VRTX stock.

Out of 17 analysts, 11 (64.71%) are recommending VRTX as a Strong Buy, 4 (23.53%) are recommending VRTX as a Buy, 1 (5.88%) are recommending VRTX as a Hold, 1 (5.88%) are recommending VRTX as a Sell, and 0 (0%) are recommending VRTX as a Strong Sell.

If you're new to stock investing, here's how to buy Vertex Pharmaceuticals stock.

What is VRTX's earnings growth forecast for 2026-2028?

(NASDAQ: VRTX) Vertex Pharmaceuticals's forecast annual earnings growth rate of 12.65% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.53%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.27%.

Vertex Pharmaceuticals's earnings in 2026 is $4,405,200,000.On average, 33 Wall Street analysts forecast VRTX's earnings for 2026 to be $4,901,300,618, with the lowest VRTX earnings forecast at $4,374,177,934, and the highest VRTX earnings forecast at $5,283,038,115. On average, 32 Wall Street analysts forecast VRTX's earnings for 2027 to be $5,394,028,654, with the lowest VRTX earnings forecast at $3,914,653,279, and the highest VRTX earnings forecast at $6,416,490,022.

In 2028, VRTX is forecast to generate $6,375,834,889 in earnings, with the lowest earnings forecast at $4,351,822,681 and the highest earnings forecast at $7,869,581,499.

What is VRTX's revenue growth forecast for 2026-2028?

(NASDAQ: VRTX) Vertex Pharmaceuticals's forecast annual revenue growth rate of 9.1% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.77%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.34%.

Vertex Pharmaceuticals's revenue in 2026 is $12,587,200,000.On average, 33 Wall Street analysts forecast VRTX's revenue for 2026 to be $3,377,620,273,224, with the lowest VRTX revenue forecast at $3,217,686,430,180, and the highest VRTX revenue forecast at $3,504,604,196,148. On average, 32 Wall Street analysts forecast VRTX's revenue for 2027 to be $3,716,244,067,688, with the lowest VRTX revenue forecast at $3,353,034,563,596, and the highest VRTX revenue forecast at $4,311,370,317,240.

In 2028, VRTX is forecast to generate $4,164,362,981,320 in revenue, with the lowest revenue forecast at $3,529,189,905,776 and the highest revenue forecast at $4,790,918,385,448.

What is VRTX's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: VRTX) forecast ROA is 26.94%, which is higher than the forecast US Biotechnology industry average of 23.26%.

What is VRTX's Price Target?

According to 17 Wall Street analysts that have issued a 1 year VRTX price target, the average VRTX price target is $562.71, with the highest VRTX stock price forecast at $641.00 and the lowest VRTX stock price forecast at $350.00.

On average, Wall Street analysts predict that Vertex Pharmaceuticals's share price could reach $562.71 by Aug 5, 2027. The average Vertex Pharmaceuticals stock price prediction forecasts a potential upside of 4.15% from the current VRTX share price of $540.26.

What is VRTX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: VRTX) Vertex Pharmaceuticals's current Earnings Per Share (EPS) is $17.33. On average, analysts forecast that VRTX's EPS will be $19.34 for 2026, with the lowest EPS forecast at $17.26, and the highest EPS forecast at $20.84. On average, analysts forecast that VRTX's EPS will be $21.28 for 2027, with the lowest EPS forecast at $15.44, and the highest EPS forecast at $25.32. In 2028, VRTX's EPS is forecast to hit $25.16 (min: $17.17, max: $31.05).

What is VRTX's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: VRTX) forecast ROE is 36.48%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.